Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AC Immune Ltd

ACIU
Current price
3.35 USD -0.05 USD (-1.47%)
Last closed 3.4 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 284 006 400 USD
Yield for 12 month +38.43 %
Week
Month
Year
ACIU
21.11.2021 - 28.11.2021

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Address: Building B, Lausanne, Switzerland, 1015

Analytics

WallStreet Target Price

10.39 USD

P/E ratio

Dividend Yield

Current Year

+4 522 630 USD

Last Year

Current Quarter

Last Quarter

Current Year

+4 522 630 USD

Last Year

Current Quarter

Last Quarter

Key Figures ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -67 063 000 USD
Operating Margin TTM -6878000 %
PE Ratio
Return On Assets TTM -24.67 %
PEG Ratio
Return On Equity TTM -43.23 %
Wall Street Target Price 10.39 USD
Revenue TTM 1 000 USD
Book Value 1.48 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 9.8 %
Dividend Yield
Gross Profit TTM -56 401 000 USD
Earnings Share -0.94 USD
Diluted Eps TTM -0.94 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ACIU

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 195380.078
Price Sales TTM 284006.4
Enterprise Value EBITDA -2.9687
Price Book MRQ 1.9772

Financials ACIU

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ACIU

For 52 weeks

1.68 USD 3.83 USD
50 Day MA 2.88 USD
Shares Short Prior Month 535 298
200 Day MA 2.62 USD
Short Ratio 11.9
Shares Short 564 879
Short Percent 1.24 %